(via TheNewswire)
Under this strategic agreement, API will play a crucial role in accelerating Voyageur’s imaging contrast medium product development, manufacturing, and commercialization. Leveraging API’s scientific and pharmaceutical expertise, the collaboration aims to facilitate regulatory approvals and expedite the market entry of Voyageur’s contrast imaging products.
This partnership will strategically target FDA,
Accelerating the development and registration of the innovative V@C60 MRI drug(Vanadium Fullerene Molecule for magnetic resonance imaginghttps://voyageurpharmaceuticals.ca/voyageur-pharmaceuticals-ltd-and-rain-cage-carbon-inc-announce-breakthrough-in-imaging-technology-with-vanadium-fullerene-molecule/
Developing novel fullerene imaging products for targeted drug delivery within the body, with a focus on applications in Oncology.
Introducing an advanced suite of new barium contrast media products, with the goal to displace current products in the market.
Expanding Voyageur’s Iodine contrast media product pipeline, including potential development of fullerene iodine products
Developing a carbon 60 based nutraceutical health supplement
"We are thrilled to embark on this groundbreaking collaboration with Voyageur, advancing healthcare through the commercialization of mineral-based active pharmaceutical ingredients for the medical imaging market," stated
By amalgamating API's regulatory expertise with Voyageur's research and development capabilities, this partnership is poised to showcase global leadership in pharmaceutical development. The collaboration exemplifies how the intersection of
About
Voyageur (
Committed to sustainability, Voyageur envisions a future of carbon neutrality.
About API:
API stands as one of
For media inquiries, please contact:
Brent@vpharma.ca | Albert@vpharma.ca |
info@vpharma.ca | https://voyageurpharmaceuticals.ca/ |
API (Applied Pharmaceutical Innovation)
tessa.vriend@appliedpharma.ca
Neither the
Cautionary Statement Regarding “Forward-Looking” Information.
This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to the perceived benefits to Voyageur from entering into the MSA; Voyageur’s expectations and timing with respect to developing pharmaceutical drugs including the Va@C60 MRI drug, fullerene imaging drugs, new barium contrast drugs, iodine contrast and fullerene iodine drugs, and nutraceutical health supplements; Voyageur’s perceived costs and other benefits from its collaboration with API; Voyageur’s anticipated plans and benefits from its relationship with API; Voyageur’s expectation that it will be able to secure the financing necessary to pursue its objectives; and other statements herein, which expressly or impliedly speak to Voyageur’s expectations for its business and operations. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties, including, without limitation, global market factors and supply chain issues, risks relating to the regulation and approval of Voyageur’s products, and general risks relating to Voyageur’s business. There can be no assurance that such information will prove to be accurate and actual.
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source